

# 6

## Other reading

### Articles

- Agarwal MB. Advances in management of sickle cell disease. *Indian Journal of Pediatrics*, August 2003, 70(8):649–654.
- Akinyanju OO et al. Initiation of prenatal diagnosis of sickle-cell disorders in Africa. *Prenatal Diagnosis*, 1999, 19:299–304.
- Alwan A, Modell B. *Community control of genetic and congenital disorders*. Cairo, World Health Organization, Regional Office for the Eastern Mediterranean, 1997 (EMRO Technical Publications Series 24).
- Arzberger P et al. An international framework to promote access to data. *Science*, 2004, 303:1777–1778.
- Attaran A, Gillespie-White L. Do patents for antiretroviral drugs constrain access to AIDS treatments in Africa? *JAMA: Journal of the American Medical Association*, 2001, 286(15):1886–1892.
- Barton JH. Patents, genomics, research, and diagnostics. *Academic Medicine*, 2002, 77(12):1339–1347.
- Barton JH. Research-tool patents: Issues for health in the developing World. *Bulletin of the World Health Organization*, 2002, 80(2):121.
- Barton JH, Strauss J. How can the developing world protect itself from biotech patent-holders? *Nature*, 2000, 406:455.
- Beck IA et al. Simple, sensitive, and specific detection of human immunodeficiency virus type 1 (HIV-1) subtype B DNA in dried blood samples for diagnosis in infants in the field. *Journal of Clinical Microbiology*, 2001, 39(1):29–33.
- Beitz C. Social and cosmopolitanism liberalism. *International Affairs*, 1999, 75(3):515.
- Bendekgey L, Hamlet-Cox D. Gene patents and innovation. *Academic Medicine*, 2002, 77(12):1373–1380.
- Benenson Y, et al. An autonomous molecular computer for logical control of gene expression. *Nature*, 2004, 429(6990):423–429.
- Black J. Regulation as facilitation: Negotiating the genetic revolution. *Modern Law Review*, 1998, 61:621–660.
- Bobrow M, Thomas S. Patents in a genetic age: The present patent system risks becoming a barrier to medical progress. *Nature*, 2001, 409:763.
- Bounpheng M et al. Rapid, inexpensive scanning for all possible *BRCA1* and *BRCA2* gene sequence variants in a single assay: Implications for genetic testing. *Journal of Medical Genetics*, 2003, 40(4):e33.

- Boyle J. *Enclosing the genome: What the squabbles over genetic patents could teach us*. 2003 (<http://www.law.duke.edu/boylesite/low/genome.pdf> accessed 19 February 2005).
- Broder S et al. Cures for the Third World's problems. *EMBO Reports*, 2002, 3(9):806.
- Buchanan A. Rawls's Law of Peoples: Rules for a vanished Westphalian world. *Ethics*, July 2000:697.
- Burch RK et al. Divergent incentives to protect Intellectual Property: A political economy analysis of North-South welfare. *Journal of World Intellectual Property*, March 2001, 3:169-195.
- Burke W et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. *JAMA: Journal of the American Medical Association*, 1997, 277(12):997-1003.
- Butler D. Genetic diversity proposal fails to impress international ethics panel. *Nature*, 1995, 377:373.
- Cantu JM, Figuera LE. Virtual molecular medicine in developing countries: The Mexican Initiative. *Molecular Medicine Today*, 2000, 6:190-192.
- Caplan A, Merz J. Patenting gene sequences. *British Medical Journal*, 13 April 1996, 312(7036):926.
- Carey NH, Crawley PE. Commercial exploitation of the human genome: What are the problems? *Human Genetic Information: Science, Law and Ethics*. Toronto, John Wiley and Sons, 1990:133-147.
- Caulfield T. Globalization, conflicts of interests and clinical research: An overview of trends and issues. *Widener Law Symposium Journal*, 2001, 8:31.
- Caulfield TA et al. Genetic technologies, health care policy and the patent bargain. *Clinical Genetics*, January 2003, 63(1):15-18.
- Caulfield TA, Gold ER. Genetic testing, ethical concerns, and the role of Patent Law. *Clinical Genetics*, 2000, 57:370-375.
- Cherniawsky K. Commercialization/Patents. In: Knoppers BM, eds, *Human DNA: Law and Policy, International and Comparative Perspectives*. Kluwer Law International, The Hague, 1997:385.
- Chong SS et al. Single-tube multiplex-PCR screen for common deletional determinants of alpha-thalassemia. *Blood*, 2000, 95(1):3602.
- Clavel C et al. Hybrid Capture II-based human papillomavirus detection, a sensitive test to detect in routine high-grade cervical lesions: A preliminary study on 1518 women. *British Journal of Cancer*, 1999, 80(9):1306-1311.
- Cook-Deegan RM, McCormack SJ. Intellectual property: Patents, secrecy, and DNA. *Science*, 2001, 293(5528):217.
- Correa CM. *Integrating public health concerns into patent legislation in developing countries*. Geneva, South Centre, October 2000 (<http://www.netamericas.net/Researchpapers/Documents/Ccorrea/Ccorrea1.pdf>, accessed 5 January 2004).
- Correa CM. Public health and patent legislation in developing countries. *Tulane Journal of Technology and Intellectual Property*, 2001, 3:1.
- Couzin J. Cancer sharpshooters rely on DNA tests for better aim. *Science*, 27 August 2004, 305:1222-1223.
- Crigger BJ. The West knows best? *Hastings Center Report*, March/April 1996, 26(2):50.
- Cullet P. Patent and medicines: The relationship between TRIPS and the human right to health. *International Affairs*, 2003 79(1):139.

- D'Amato RF et al. Rapid diagnosis of pulmonary tuberculosis by using Roche AMPLICOR Mycobacterium tuberculosis PCR test. *Journal of Clinical Microbiology*, 1995, 33(7):1832–1834.
- Daniels N. *Just Health Care*. Cambridge and New York, Cambridge University Press, 1985.
- Davies K. Playing by Aussie rules (Conversation: Mervyn Jacobson). *Bio-IT World* (www.bio-itworld.com), 13 August, 2003.
- Dennis C. Geneticists question fees for use of patented “junk” DNA. *Nature*, 8 May 2003, 423:105.
- Dickson D. Open access to sequence data will boost hunt for breast cancer gene. *Nature*, 1995, 378:425.
- Drahoš P, Braithwaite J. Intellectual property, corporate strategy, globalization: TRIPS in context. *Wisconsin International Law Journal*, 2002, 20:451 (Proceedings of 2002 Conference Access to Medicines in the Developing World).
- Dryer O. US awards patent for tribesman's DNA. *British Medical Journal*, 1995, 311(7018):1452a.
- Eisenberg RS, Nelson RR. Public vs. proprietary science: A fruitful tension? *Academic Medicine*, 2002, 77(12):1392–1399.
- Eisenberg RS. Patent swords and shields. *Science*, 2003, 299:1018–1019.
- Enriquez J, Martinez R. The next revolution: Who's ready? Who's not. *Perspectives in Health Magazine* (The Magazine of the Pan American Health Organization), Special Centennial Edition, 2002, 7:1 ([http://www.paho.org/English/DPI/Number14\\_article4\\_5.htm](http://www.paho.org/English/DPI/Number14_article4_5.htm), accessed 15 December 2003).
- Ergenziger E, Spruill M. Basic science in US universities can infringe patents. *The Scientist*, 10 March 2003, 17(5):43.
- Fidle DP. Racism or realpolitik? U.S. foreign policy and the HIV/AIDS catastrophe in sub-Saharan Africa. *Journal of Gender, Race and Justice*, 2003, 7:97.
- Friedman MA et al. Out-licensing: A practical approach of improvement of access to medicines in poor countries. *Lancet*, 2003, 361:341–44.
- Genetic diversity proposal fails to impress international ethics panel. *Nature*, 5 October 1995.
- Gitter D. International conflicts over patenting human DNA sequences in the United States and the European Union: An argument for compulsory licensing and a fair-use exemption. *New York University Law Review*, 2001, 76:1623–1691.
- Gold ER. From theory to practice: Health care and the patent system. *Health Law Journal*, September 2003, Special Edition 2003: Precedent & Innovation: Health Law in the 21st Century.
- Gold ER. Gene patents and medical access. *Intellectual Property Forum*, 2000, 49:20–27.
- Gold ER. Making room, Integrating basic research, health policy and ethics into patent law. In: Caulfield T, Williams-Jones B, eds, *The Commercialisation of genetic research, Ethical, legal and policy issues*. New York, Kluwer Academic/Plenum Publishers, 1999:63–78.
- Gold ER. Moving the gene patent debate forward: A framework for achieving compromise between industry and civil society. *Nature Biotechnology*, 2000, 18:1319–1320.
- Gold ER. Owning our bodies: An examination of property law and biotechnology. *San Diego Law Review*, 1995, 32(4):1167–1247.
- Gold ER. SARS genome patent: Symptom or disease? *Lancet*, 2003, 361:2002–2003.

- Gold ER et al. Gene patents and the standard of care. *Canadian Medical Association Journal*, 6 August 2003, 167(3):256–57.
- Gold ER, Caulfield TM. The moral tollbooth: A method that makes use of the patent system to address ethical concerns in biotechnology. *Lancet*, 2002, 350:2268–2270.
- Gold ER, Gallochat A. The European directive: Past and prologue. *European Law Journal*, September 2001, 7(3):331–366.
- Gold ER, Lam DK. Balancing trade in patents: Public non-commercial use and compulsory licensing. *Journal of World Intellectual Property*, 2003, 6(1):5–31.
- Granda H et al. Cuban program for prevention of sickle cell disease. *Lancet*, 1991, 337:152–153.
- Greco A. From bench to boardroom: Promoting Brazilian biotech (Profile: Fernando Reinach). *Science*, 2003, 300:1366–1367.
- Hanson MJ. Biotechnology and commodification within health care. *Journal of Medicine and Philosophy*, 1999, 24:267.
- Herdegen M. Patenting human genes and other parts of the human body under EC biotechnology directive. *Bio-Science Law Review*, 2001:13.
- Heredero L. Comprehensive national genetic program in a developing country—Cuba. *Birth Defects Original Article Series*, 1992, 28(3):52–57.
- Hill AV. Molecular epidemiology of the thalassaemias (including haemoglobin E). *Baillieres Clinical Haematology*, January 1992, 5(1):209–38.
- Hoffman SL. Research (Genomics) is crucial to attacking malaria. *Science*, November 2000, 290:5496, 1509.
- Human Genetic Organisation Ethics Committee. HUGO urges genetics benefit-sharing. *Community Genetics*, 2000, 3:88–92.
- Ida R. Human genome as the common heritage of mankind. *Bioethics in Asia*, 1998:59–63 (<http://www.biol.tsukuba.ac.jp/~macer/asiae/biae59.html>, accessed 5 January 2004).
- James JS. India research opportunities, price and patent problems. *AIDS Treatment News Issue*, 1999:321.
- Jia H. IP litigation in China could drive innovation. *Nature Biotechnology*, 2004, 22(4):368.
- Jones JS. Biotechnology “roadmap” for South Africa unveiled. *SciDevNet*, 17 September 2004.
- Kass LT, Nitabach MN. A roadmap for biotechnology patents? Federal Circuit precedent and the PTO’s new examination guidelines. *American Intellectual Property Law Association Quarterly Journal*, 2002, 30:233–265.
- Kent A. BC sidesteps patent claim, Transfers BRCA gene testing to Ontario. *Canadian Medical Association Journal*, 21 January 2003, 68:2.
- Knoppers BM. Biotechnology: Sovereignty and sharing. In: Caulfield T, Williams-Jones B, eds., *The Commercialisation of genetic research, ethical, legal and policy issues*. New York, Kluwer Academic/ Plenum Publishers, 1999:1–11.
- Koch WH. Technology platforms for pharmacogenomic diagnostic assays. *Nature Reviews: Drug Discovery*, 2004, 3:749–761.
- Kongolo T. The African Intellectual Property Organizations: The necessity of adopting one uniform system for all Africa. *Journal of World Intellectual Property*, 2000:265–288.
- Lanjouw JO. A new global patent regime for diseases: US and international legal issues. *Harvard Journal of Law & Technology*, 2002:16:85.

- Lazzarini Z. Making access to pharmaceuticals a reality: Legal options under TRIPS and the case of Brazil. *Yale Human Rights & Development Law Journal*, 2003, 6:103.
- Le Saux O et al. A spectrum of ABCC6 mutations is responsible for pseudoxanthoma. *American Journal of Human Genetics*, 2001, 69:749–764.
- Lesko JL, Woodcock J. Translation of pharmacogenomics and pharmacogenetics: A regulatory perspective. *Nature Reviews*, September 2004, 3:763–769.
- Lichtman MA, Hunter MD, Lidars GJ. Intellectual property—the dispute between research institutions and voluntary health agencies. *Nature Biotechnology*, 2004, 22(4):385–386.
- Lindpaintner K. Genetics and genomics: Impact on drug discovery and development. *Annual Conference on Research in Computational Molecular Biology, Proceedings of the fifth annual international conference on Computational Biology*. Basel, GSIA, 2000:221–222.
- Lock M. The Human Genome Diversity Project: A perspective from cultural anthropology. In: Knoppers BM, ed., *Human DNA: Law and Policy, International and Comparative Perspectives*. The Hague, Kluwer Law International, 1997.
- Macklin R. The ethics of gene patenting. In: Thompson AK, Chadwick R, eds. *Genetic Information*. New York, Kluwer Academic/Plenum Publishing, 1999:129–37.
- Marks SP. Health and human rights: The expanding international agenda. *American Society of International Law Proceedings*, 2001, 95:64.
- Marks SP. Tying Prometheus down: The International Law of Human Genetic Manipulation. *Chicago Journal of International Law*, 2002, 3:115.
- Martinez PA et al. Simple and rapid detection of the newly described mutations in the HLA-H Gene. *Blood*, 1997, 89:1835–1836.
- Martone M. The ethics of the economics of patenting the human genome. *Journal of Business Ethics*, 1998, 17:1679.
- Maskus K. Intellectual property rights in the global economy. Institute for International Economics, 2000 ([http://www.iie.com/publications/bookstore/publication.cfm?Pub\\_ID=99](http://www.iie.com/publications/bookstore/publication.cfm?Pub_ID=99), accessed 15 January 2003).
- Matthijs G, Halley D. European-wide opposition against the breast cancer gene patents. *European Journal of Human Genetics*, 2002, 10:783–784.
- Mayor S. Charity makes cancer gene freely available across Europe. *British Medical Journal*, 21 February 2004, 328:423.
- McCabe KW. The January 1999 Review of Article 27 of the TRIPs Agreement: Diverging views of developed and developing countries toward the patentability of biotechnology. *Journal of Intellectual Property Law*, 1998, 6(41):41–67.
- McLeland L, O’Toole JH. Patent systems in less developed countries: The Cases of India and the Andean Pact countries. *Journal of Law Technology*, 1987:226–247.
- McManis CR. Intellectual property, genetic resources and traditional knowledge protection: Thinking globally, acting locally. *Cardozo Journal of International and Comparative Law*, 2003, 11:547.
- Merz JF. Disease gene patents: Overcoming unethical constraints on clinical laboratory medicine. *Clinical Chemistry*, 1999, 45(3):324–330.
- Merz JF et al. Protecting subjects’ interests in genetics research. *American Journal of Human Genetics*, 2002, 70:965–971.

- Morgan S et al. Predictive genetic tests and health system costs. *Canadian Medical Association Journal*, 15 April 2003, 168(8):989–991.
- Mugabe J. *Centers of Excellence in Science and Technology for Africa's sustainable development: Towards new forms of regional and sub-regional networks*. For African Ministerial Conference on Science and Technology for Development (<http://www.touchtech.biz/nepad/files/documents/126.pdf>, accessed 15 January 2004).
- Mugabe J. *Intellectual property protection and traditional knowledge: An exploration in international policy discourse*. For World Intellectual Property Organization on behalf of African Centre for Technology Studies. African Centre for Technology Studies, Kenya, 1998.
- Nau JY. Une Pétition Lancée par le Prof. Mattei S'oppose aux Brevets sur les Gènes Humains. *Le Monde*, 26 May 2000.
- Nelsen L. The role of university technology transfer operations in assuring access to medicines and vaccines in developing countries. *Yale Journal of Health Policy Law and Ethics*, January 2003, 3(2):301–308.
- Nerozzi MN. The battle over life-saving pharmaceuticals: Are developing countries being 'TRIPped' by developed countries? *Villanova Law Review*, 2002, 47:605.
- Nolff M. Compulsory patent licensing in view of the WTO Ministerial Conference Declaration on the TRIPS Agreement and Public Health. *Journal of the Patent and Trademark Office Society*, 2002, 84:133.
- Nwabueze RN. Ethnopharmacology, patents and the politics of plants' genetic resources. *Cardozo Journal of International and Comparative Law*, 2003, 11:585.
- Page AK. Prior agreements in international clinical trials: Ensuring the benefits of research to developing countries. *Yale Journal of Health Policy, Law, and Ethics*, 2002, 3:35.
- Perkel C. Ontario defying American gene company by using new breast-cancer test. *Canadian Press*, 6 January 2003 ([http://mediresource.sympatico.ca/health\\_news\\_detail.asp?channel\\_id=12&news\\_id=578](http://mediresource.sympatico.ca/health_news_detail.asp?channel_id=12&news_id=578), accessed 5 January 2003).
- Petrou M, Modell B. Prenatal screening for haemoglobin disorders. *Prenatal Diagnosis*, 1995, 15:1275–1295.
- Poste G. The case for genomic patenting. *Nature*, 1995, 387:534.
- Pridan-Frank S. Human-genomics: A challenge to the rules of the game of international law. *Columbia Journal of International and Comparative Law*, 2002, 40:619.
- Ragavan S. Can't we all get along?: A case for a workable patent. *Arizona State Law Journal*, 2003, 35:117.
- Ragavan S. Protection of traditional knowledge. *Minnesota Intellectual Property Review*, 2001, 2:1.
- Ramirez JL, Holmes D. The need for genomics networking in Latin America. *Science and Development Network* ([www.SciDev.net](http://www.SciDev.net)), 14 August 2003.
- Rapp RT, Rozer RP. Benefits and costs of Intellectual Property protection in developing countries. *Journal of World Trade*, 1990, 24:75–102.
- Raskins S et al. DNA analysis of cystic fibrosis in Brazil by direct PCR amplification from Guthrie cards. *American Journal of Medical Genetics*, 1 July 1993, 46(6):665–659.
- Rosendal GK. The politics of patent legislation in biotechnology: An international view. *Biotechnology Annual Review*, 1995, 1:453.
- Roses AD. Pharmacogenetics and drug development: The path to safer and more effective drugs. *Nature Reviews*, September 2004, 5:645–656.

- Russo E. Merging IT and biology. *The Scientist*, 2000, 14(23):8.
- Salotra P et al. Development of a species-specific PCR assay for detection of *Leishmania donovani* in clinical samples from patients with kala-azar and post-kala-azar dermal leishmaniasis. *Journal of Clinical Microbiology*, 2001, 39(3):849–854.
- Savithri HS et al. Predictive testing for familial adenomatous polyposis in a rural South Indian community. *Clinical Genetics*, 2000, 58(1):57–60.
- Service RS. Gene and protein patents get ready to go head to head. *Science*, 7 December 2001, 294(5549): 2082.
- Shattuck-Eidens D et al. *BRCA1* sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. *JAMA: Journal of the American Medical Association*, 1997, 278(15):1242–1250.
- Sheremeta L, Gold ER. Creating a patent clearinghouse in Canada: A solution to problems of equity and access. *Health Law Review*, 2003, 11(3):17–19.
- Spectar JM. Patent necessity: Intellectual property dilemmas in the biotech dominant treatment equity for developing countries. *Houston Journal of International Law*, 2001, 24:227.
- Streit C et al. CFTR gene: Molecular analysis in patients from South Brazil. *Molecular Genetics and Metabolism*, April 2003, 78(4):259–264.
- Streit C et al. CFTR gene: Molecular analysis in patients from South–Brazil. *Molecular Genetics and Metabolism*, 2003, 78:259.
- Taubes G. Scientists attacked for patenting Pacific tribe. *Science*, 17 November 1995, 270(5239).
- Taylor AL. Globalization and biotechnology: Unesco and an international strategy to advance human rights and public health. *American Journal of Law & Medicine*, 1999:479.
- Thomas SM et al. Ownership of the human genome. *Nature*, 1996, 380:387–388.
- Thomas SM et al. Public-sector patents on human DNA. *Nature*, 1997, 388:709.
- Verma IC. Burden of genetic disorders in India. Symposium: Genetics for Pediatricians-I. *Indian Journal of Pediatrics*, 2000, 67(12):893–98.
- Wadman M. Ethical terms set for breast cancer test. *Nature*, 27 November 1997, 390:324.
- Warner JP, Barron LH, Brock DJ. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntington's disease chromosomes. *Molecular and Cellular Probes*, 1993, 7(3):235–9.
- Warner S. Diagnostics + therapy = theranostics. *The Scientist*, 30 August 2004, 18(16):38.
- Weinshilboum R, Wang L. Pharmacogenomics: Bench to bedside. *Nature Reviews: Drug Discovery*, 2004, 3(9):739–748.
- Wheeler C, Berkley S. Initial lessons from public-private partnerships in drug and vaccine development. *Bulletin of the World Health Organization*, 2001, 79:728.
- Williamson AR. Gene patents: Are they socially acceptable monopolies or an unnecessary hindrance to research. *Drug Discovery Today*, November 2001, 6(21):1092–1093.

Willison DJ, Macleod SM. Patenting of genetic material: Are the benefits to society being realised? *Canadian Medical Association Journal*, 6 August 2002, 167(3):259–262.

Winnick E. DNA sequencing industry sets its sights on the future. *The Scientist*, 27 September 2004, 18(18):44.

Wolfson JR. Social and ethical issues in nanotechnology: Lessons from biotechnology and other high technologies. *Biotechnology Law Report*, 2003, 22:376.

## Books

Boyle J. *Shamans, software & spleens: Law and the construction of the information society*. Cambridge, Massachusetts and London, Harvard University Press, 1996.

Cain B. *Legal aspects of gene technology*. London, Thompson, 2003.

Gold ER. *Body parts: Property rights and the ownership of human biological materials*. Washington, D.C., Georgetown University Press, 1996.

Greider G. *One world, ready or not: The manic logic of global capitalism*. New York, Simon and Shuster, 1997.

Knoppers BM, ed. *Human DNA: Law and policy, international and comparative perspectives*. New York, Kluwer, 1997.

Laurie G. *Genetic privacy: A challenge to medico-legal norms*. Cambridge, Cambridge University Press, 2002.

Mason S, Megone C, eds. *European neonatal research: Consent, ethics committees and law*. Aldershot, Ashgate, 2001.

Radin M. *Contested commodities*. Cambridge, Harvard University Press, 1996.

Silver LM. *Remaking Eden*. New York, Avon Books, 1997.

## Proceedings and symposiums

Fidler DP. Introduction to written symposium on Public Health and International Law. *Chicago Journal of International Law*, 2002:3.

*Fifth Meeting of the Secretary's Committee on Genetic Testing*, Volume III. United States, Secretary's Advisory Committee on Genetic Testing (SACGT), 7 June 2000 (<http://www4.od.nih.gov/oba/sacgt/sacgtmtg.htm>, accessed 9 March 2004).

Nelkin D. A Brief history of the political work of genetics. Symposium: Legal & Ethical Issues in Genetic Research or Indigenous Populations. *Jurimetrics*, 2002, 42:121.

Pai GS et al. Challenges in human genetics in India in the new millennium. Symposium: Genetics for Pediatricians-I. *Indian Journal of Pediatrics*, 2000, 67(11):809–811.

*Report of a WHO meeting on collaboration in medical genetics*. Geneva, World Health Organization, 2002 (WHO/HGN/WG/02.2).

Scidev. Africa's Scientific Revival Day now recognized. *Scidev Workshop*, Uganda, 29 September to 3 October 2002 (<http://www.sciencenewsdev.co.ke/special-f.htm>, accessed 15 January 2004).

Sheremeta L, Gold ER. *Creating a patent clearinghouse in Canada: A solution to problems of equity and access?* poster presentation, GELS Winter Symposium 2003, 6–8 February 2003, Montreal, Quebec.

Verma IC. Burden of genetic disorders in India. Symposium: Genetics for Pediatricians-I. *Indian Journal of Pediatrics*, 2000, 67(12):893–98.

Verma IC et al. Genetic counseling and prenatal diagnosis in India—Experience at Sir Ganga Ram Hospital. *Indian Journal of Pediatrics*, 2003, 70:293–97.

World Health Assembly Resolution WHA56.27. *Intellectual property rights, innovation and public health*. Fifty-sixth World Health Assembly, 28 May 2003 ([http://www.who.int/gb/ebwha/pdf\\_files/WHA56/ea56r27.pdf](http://www.who.int/gb/ebwha/pdf_files/WHA56/ea56r27.pdf) accessed February 2005).

## Reports

### American College of Obstetricians and Gynaecologists

*Screening for Canavan Disease, fact sheet number 212*. American College of Obstetricians and Gynaecologists, November 1998 (<http://www.tay-sachs.org/medical.php> accessed 5 January 2004).

### British Society for Human Genetics (BSHG)

*Statement on patenting and clinical genetics*. United Kingdom, British Society for Human Genetics, 1 February 1998.

### Canada Department of Justice

Gold ER, Caulfield TA. *Human genetic inventions, patenting and human rights*. Ottawa, Department of Justice, Government of Canada, 2003.

### Canadian Cancer Society

*The patenting of BRCA1 and 2 genes facts sheet*. Canada, The Canadian Cancer Society ([http://www.cancer.ca/ccs/internet/standard/0,3182,3172\\_31282995\\_32777862\\_langId-en,00.html](http://www.cancer.ca/ccs/internet/standard/0,3182,3172_31282995_32777862_langId-en,00.html), accessed 30 December 2003).

Patenting of genes and gene sequences. Canada, The Canadian Cancer Society, 17 June 2003 ([http://www.cancer.ca/ccs/internet/standard/0,3182,3172\\_61901275\\_\\_langId-en,00.html](http://www.cancer.ca/ccs/internet/standard/0,3182,3172_61901275__langId-en,00.html), accessed 15 December 2003).

### Center for Advanced Studies at the University of Buenos Aires

Carlos M Correa. *Intellectual property rights and the use of compulsory licenses: Options for developing countries* [Working Paper]. Buenos Aires, Center for Advanced Studies at the University of Buenos Aires, A, 1999.

### Center for International Environmental Law

Downes D. *The 1999 WTO review of life patenting under TRIPS* [Revised discussion paper]. Washington, D.C, Center for International Environmental Law, September 1998:1.

### Centre for Law and Genetics

Nicol D, Nielsen J. Patents and medical biotechnology: An empirical analysis of the issues facing the Australian industry. Tasmania, Australia, Centre for Law and Genetics, 2003 (Occasional Paper No. 6).

### Centre for Management of Intellectual Property in Health Research and Development

Mahoney RT ed. *Handbook of best practices for management of intellectual property in health research and development*. Oxford, UK, Centre for Management of Intellectual Property in Health Research and Development, November 2003.

### Conference of the Parties to the Convention on Biological Diversity

*Sixth Meeting of the Conference of the Parties to the Convention on Biological Diversity, Decision VI/24, Access and benefit-sharing as related to genetic resources*. The Hague, April 2002 (<http://www.biodiv.org/welcome.aspx>, accessed 5 January 2004).

**Econexus and GeneWatch UK**

*Patenting genes—Stifling research and jeopardising healthcare.* United Kingdom, Econexus and GeneWatch UK, 1 April 2001 (<http://www.genewatch.org/Publications/Patenting/Patents.pdf>, accessed 3 January 2004).

**Economic and Social Research Council**

ESRC Genomics Scenarios Project: 3. *Key drivers of genomics: forecasts for 2015.* Economic and Social Research Council, January 2002.

**Global Forum for Health Research**

*The 10/90 Report on Health Research.* Geneva, Global Forum for Health Research, 2000.

**International Association for the Protection of Intellectual Property**

*Patentability requirements and scope of protection of Expressed Sequence Tags (ESTs), Single Nucleotide Polymorphisms (SNPs) and entire genome.* Sorrento, International Association for the Protection of Intellectual Property, 14 April 2000 (<http://www.aippi.org/reports/resolutions/res-q150-e-exco-2000.htm>, accessed 5 January 2004).

**International Intellectual Property Institute**

*Patent protection and access to HIV/AIDS pharmaceuticals in sub-Saharan Africa.* Washington DC, International Intellectual Property Institute, 2000 (<http://www.iipi.org/activities/Research/HIV%20AIDS%20Report.pdf> accessed 21 January 2004).

**Medical Research Council of South Africa**

*Guidelines on ethics for medical research: Reproductive biology and genetic research.* Tygerberg, The Medical Research Council of South Africa, 1 April 2002 (<http://www.sahealthinfo.org/ethics/ethicsbook2.pdf>, accessed 15 December 2003).

**National Institute for Health Care Management Research and Educational Foundation**

*Changing patterns of pharmaceutical innovation.* Washington, DC, The National Institute for Health Care Management Research and Educational Foundation, May 2002.

**National Research Council**

*Patents in the knowledge-based economy.* National Research Council, USA, 2003 (<http://books.nap.edu/books/0309086361/html/297.html#pagetop> accessed 21 January 2003).

**Organisation for Economic Development and Cooperation**

*Genetic inventions, intellectual property rights and licensing practices: Evidence and policies.* Paris, Organisation for Economic Development and Cooperation (OECD), 2002:50.

**Royal Society**

Needham R et al. *Keeping science open: The effects of intellectual property policy on the conduct of science.* London, The Royal Society, April 2003.

**United Nations Commission on Human Rights**

Motoc A. *Specific human rights issues. Universal Declaration on the Human Genome and Human Rights.* Geneva, UN Commission on Human Rights, 2002 (doc.E/CN.4/sub.2/2002/37).

**United Nations Educational Social and Cultural Organization**

*Report of the IBC on ethics, intellectual property and genomics.* UNESCO, International Bioethics Committee (IBC), 10 January 2002.

**United States Federal Trade Commission**

*To promote innovation: The proper balance of competition and patent law and policy.* Washington, DC, Federal Trade Commission, October 2003.

**University of Toronto Joint Center for Bioethics**

*Top 10 biotechnologies for improving health in developing countries.* Toronto, Program in Applied Ethics and Biotechnology and Canadian Program on Genomics and Global Health, University of Toronto Joint Center for Bioethics, 2003 (<http://www.utoronto.ca/jcb/pdf/top10biotechnologies.pdf>, accessed 30 December 2004).

**World Bank**

Fink C. *How stronger patent protection in India might affect the behavior or transnational pharmaceutical industries.* Development Research Group, World Bank, 2000 (<http://econ.worldbank.org/docs/1106.pdf>, accessed 15 January 2004).

Yang G, Maskus KE. *Intellectual property rights, licensing, and innovation.* World Bank, 2003 (Policy Research Working Paper 2973).

**World Health Organization**

Berg K, Boulyjenkov V, Christen Y. *Genetic approaches to noncommunicable diseases.* Geneva, World Health Organization and Fondation IPSEN, Springer-Verlag, 1996:1–155.

*Fifty facts from the World Health report 1998, Global health situation and trends 1955–2025.* Geneva, World Health Organization, 1998 (<http://www.who.int/whr2001/2001/archives/1998/pdf/factse.pdf>, accessed 30 December 2003).

*Genomics and World Health: Report of the Advisory Committee on Health Research.* Geneva, World Health Organization, 2002 (EB112/4).

*Guidelines for control of haemoglobin disorders.* Geneva, World Health Organization, 1994 (WHO/HDP/HB/GL/94.1).

*Human genetic technologies: implications for preventative care.* Geneva, World Health Organization, 2001 (WHO/HGN/Rep/02.1).

*Report of a WHO meeting on collaboration in medical genetics.* Geneva, World Health Organization, 2002 (WHO/HGN/WG/02.2).

*The molecular genetic epidemiology of cystic fibrosis.* Geneva, World Health Organization, 2004 (WHO/HGN/CF/WG/04.02).

*World Health Report 1999: Making a difference, Part I.* Geneva, World Health Organization, 1999 (<http://www.who.int/whr2001/2001/archives/1999/en/pdf/whr99.pdf>, accessed 29 December 2003).

**Patent office publications**

India Patents Office. *Exclusive Market Rights* (<http://www.patentoffice.nic.in/ipr/patent/emr.htm>, accessed 26 February 2004)

United States Patent and Trademark Office, Utility Examination Guidelines. 66:4 *Federal Register*, 5 January 2001, 1092.

**Case Law****Canada**

*Schmeiser v. Monsanto Canada Inc.* [2002] 21 C.P.R. (4<sup>th</sup>) 1 affirming 12 C.P.R. (4<sup>th</sup>) 204 (FCA).

*Harvard College v. Canada* (Commissioner of Patents), (2002) SCC 76.

## United States of America

*Chou v. Univ. of Chicago*, 254 F.3d 1347, 1363 (Fed. Cir. 2001).

*Greenberg v. Miami Children's Hospital Research Institute, Inc* 16 Fla.L. Weekly Fed D 417.

## Legislation

Agreement on Trade-Related Aspects of Intellectual Property Rights, being Annex 1C of the Marrakesh Agreement Establishing the World Trade Organization, 33 I.L.R. 1197 (1993).

Brazil. Patent Law 9.279 of 1997.

China. Patent Law 1985, amended in 1992 and in 2003.

Convention on Biological Diversity, Rio de Janeiro, 5 June 1992 (<http://www.biodiv.org/doc/legal/cbd-en.pdf>, accessed 5 January 2004).

France. *Projet de loi relatif à la protection des inventions biotechnologiques*. France: Sénat. Session ordinaire de 2001–2002; 2001 Nov 6. No 55. Art. 11. ([www.senat.fr/leg/pjl01-055.html](http://www.senat.fr/leg/pjl01-055.html), accessed 6 January 2004).

Genomic Research and Diagnostic Accessibility Act of 2002, H.R. 3967, 107<sup>th</sup> Cong., 2nd Sess. (2002).

India. Patents Act 1970.

International Treaty on Plant Genetic Resources for Food and Agriculture (ITPGRFA), FAO, November 2001 (<ftp://ext-ftp.fao.org/ag/cgrfa/it/ITPGRRe.pdf>, accessed 5 January 2004).

United Nations Convention on the Law of the Sea. Montego Bay, 1982 ([http://www.un.org/Depts/los/convention\\_agreements/texts/unclos/closindx.htm](http://www.un.org/Depts/los/convention_agreements/texts/unclos/closindx.htm), accessed 5 January 2004).

## Statements

### European Group on Ethics in Science and New Technologies

*Opinion No. 16, Ethical aspects of patenting inventions involving human stem cells*. Brussels, European Group on Ethics in Science and New Technologies, 7 May 2002 ([http://europa.eu.int/comm/european\\_group\\_ethics/avis3\\_en.htm](http://europa.eu.int/comm/european_group_ethics/avis3_en.htm), accessed 14 January 2004).

### European Council

*Council agreement relating to Community patents*. Luxembourg, European Council, 15 December 1989 (89/695/EEC) ([http://europa.eu.int/smartapi/cgi/sga\\_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=en&numdoc=41989A0695\(01\)&model=guichett](http://europa.eu.int/smartapi/cgi/sga_doc?smartapi!celexapi!prod!CELEXnumdoc&lg=en&numdoc=41989A0695(01)&model=guichett), accessed 25 January 2004).

### Government of India

*Ethical policies on the human genome, genetic research and services*. New Delhi, Department of Biotechnology—Government of India, June 2001 (<http://dbtindia.nic.in/publication/publicmain.html>, accessed 13 January 2004).

### Human Genome Organisation

*Statement on benefit sharing*. HUGO, 2000 (<http://www.gene.ucl.ac.uk/hugo/benefit.html>, accessed 5 January 2004).

*Statement on patenting DNA sequences*. HUGO, April 2000 (<http://www.hugo-international.org/hugo/patent2000.html>, accessed 12 January 2004).

*Statement on patenting issues related to early release of raw sequence data*. HUGO, 1997 (<http://www.gene.ucl.ac.uk/hugo/ip1997.htm>, accessed 13 January 2004).

**Indigenous Peoples Council on Biocolonialism**

*A resolution to oppose the human genome diversity project and condemning unethical genetic research on indigenous peoples.* Wadsworth, Indigenous People Council on Biocolonialism (IPCB), 15 January 1998 ([http://www.ipcb.org/resolutions/htmls/model\\_resolution\\_hgdp.html](http://www.ipcb.org/resolutions/htmls/model_resolution_hgdp.html), accessed 13 January 2004).

*The "Heart of the Peoples" Declaration.* Fort Belknap Reservation, Indigenous Peoples Council on Biocolonialism (IPCB), 7 August 1997 ([http://www.ipcb.org/resolutions/htmls/dec\\_heartopeoples.html](http://www.ipcb.org/resolutions/htmls/dec_heartopeoples.html), accessed 13 January 2004).

**International Federation of Gynecology and Obstetrics**

*Recommendations on ethical issues in obstetrics and gynaecology-patenting human genes.* FIGO Committee on the Study of Ethical Aspects of Human Reproduction. *International Digest of Health Legislation*, 1997, 48:447.

**United Nations**

*UN Agreement governing the activities of States on the Moon and other celestial bodies.* New York, 18 December 1979.